Our Science – Day Website
Chi-Ping Day, Ph.D.
Dr. Day's research focuses on the development of transgenic and preclinical models of recurrent and metastatic diseases, and identification of therapeutic targets of metastatic melanoma.
1.Day CP, Carter J, Bonomi C, Hollingshead M, Merlino G. (2012) Preclinical therapeutic response of residual metastatic diseases is distinctive from primary tumor of origin. Int. J. Cancer 130(1):190
2. Day CP, Carter J, Bonomi C, Esposito D, Crise B, Ortiz-Conde B, Hollingshead M, Merlino G. (2009) Lentivirus-mediated bifunctional cell labeling for in vivo melanoma study. Pigment Cell Melanoma Res. 22(3):283-95.
3. Zaidi MR*, Day CP*, Merlino G. (2008) From UVs to metastases: modeling melanoma initiation and progression in the mouse. J. Invest. Dermatol. 128:2381-91. (*equal contribution)
1. 'Lentiviral vectors for long term in vivo expression of dual fluorescence/luminescence reporters' (2011) Inventors: Dominic Esposito, Chi-Ping Day, and Glenn Merlino. NIH Employee Invention Report Reference No. E‐132‐2011.
2.'A bioimaging marker‐tolerant mouse allowing consistent tumor labeling and monitoring in an immunocompetent mouse model' (2010) Inventors: Chi-Ping Day and Glenn Merlino. NIH Employee Invention Report Reference No. E‐173‐2010.
This page was last updated on 2/21/2013.